Skip to main content

Table 3 Overview of included studies with their characteristics

From: Safe use of radiopharmaceuticals in patients with chronic kidney disease: a systematic review

References Year Study design Number of patients Radiopharmaceutical Indication Dose (MBq) Stage of kidney failure (CKD) Type of dialysis (number of patients) Timing of dialysis after administration radiopharmaceutical
Akers et al. (2016) 2016 COS 58 [18F]fludeoxyglucose PET/CT 370–555 1–5 NA NA
Aktaş et al. (2008) 2008 CCS 10 [131I]sodium iodine TC 1110–3700 5 HD (6); CAPD (4) 24 h continued every day for 5d; CAPD increased from 4 to 6–8 times a day
Alevizaki et al. (2006) 2006 CS 5 [131I]sodium iodine PTC 1110–2590 5 HD (4); IPD (1) 48 h, and 2 patients also 96 h
Bhat et al. (2017) 2017 CR 1 [131I]sodium iodine PTC 1850 5 HD 15 h, 27 h, 43 h
Courbon et al. (1997) 1997 CR 1 [131I]sodium iodine TC 3700 5 HD 2d, 4d
Courbon et al. (2006) 2006 CS 2 [131I]sodium iodine TC 3700 5 HD 72 h, 122 h-144 h
Culpepper et al. (1992) 1992 CR 1 [131I]sodium iodine FTC 4773 5 HD 24 h,43 h,66 h
Daumerie et al. (1996) 1996 CS 3 [131I]sodium iodine PTC 2 treatments of 925 5 HD 2d, 3d
Demko et al. (1998) 1998 CR 1 [131I]sodium iodine TMNG 1045.62 5 HD 24 h
Driedger et al. (2006) 2006 CS 3 [131I]sodium iodine PTC 3700; 3700; 2500 5 HD (2); CAPD (1) NA
El-Zeftawy et al. (2017) 2017 CCS 27 [131I]sodium iodine DTC Mean dose 5550 3 and 4 NA NA
Fofi et al. (2013) 2013 CS 2 [131I]sodium iodine PTC 1850 5 CHD 24 h, 48 h
Holst et al. (2005) 2005 CR and TM 1 [131I]sodium iodine PTCa 3637 5 HD 2d, 3d, 4d
Howard and Glasser (1981) 1981 CR 1 [131I]sodium iodine PTC 740 5 HD NA
Jiménez et al. (2001) 2001 CS 3 [131I]sodium iodine PTC 2775; 3219; 4440 5 HD 24 h, 48 h, 72 h, 96 h, 144 h
Kaptein et al. (2000) 2000 CS 2 [131I]sodium iodine PTC 980; 1110 5 CAPD 3–5 times a day
Kode et al. (2017) 2017 CCS 30 [18F]fludeoxyglucose PET/CT 5.18 /kg 4 and 5 NAb NA
Laffon et al. (2008) 2008 TM NA [18F]fludeoxyglucose NA NA NA NA NA
Magné et al. (2002) 2002 CR 1 [131I]sodium iodine PTC 1850 5 HD 24 h, 72 h, 144 h
McKay and Malaroda (2019) 2019 TM NA [131I]sodium iodinec TD NA 5 NA Several timing intervals were simulated
McKillop et al. (1985) 1985 CR 1 [131I]sodium iodine GD 462.5 5 HD 3d
Mello et al. (1994) 1994 CR 1 [131I]sodium iodine PTC 2 treatments of 3700 5 HD 41 h, 89 h
Minamimoto et al. (2007) 2007 COS 20 [18F]fludeoxyglucose PET/CT 210–360 NAd NA NA
Miyasaka et al. (1997) 1997 CR 1 [131I]sodium iodine GD 740 5 HD 24 h
Morrish et al. (1990) 1990 CR 1 [131I]sodium iodine PTC 1850; 4440; 5550; 9250 5 HD 48 h, 96 h, 144 h
Pahlka and Sonnad (2006) 2006 TM NA [131I]sodium iodine TC NA 5 HD; CAPD Several timing intervals were simulated
Sinsakul and Ali (2004) 2004 CS 2 [131I]sodium iodine PTC 3700; 5809 5 HD 20 h-24 h
Tobes et al. (1989)e 1989 CCS 1 [131I]iobenguane PC 18.5 5 HD NA
Toriihara et al. (2015) 2015 CCS 24 [18F]fludeoxyglucose PET/CT 3.7 /kg 5 HD NA
Toubert et al. (2001) 2001 CR 1 [131I]sodium iodine FTC 814 5 CAPD 4 times a day
Vermandel et al. (2020) 2020 CS 6 [131I]sodium iodine TC 1842–3747 5 HD 42 h, 90 h
Wang et al. (2003) 2003 CS 2 [131I]sodium iodine PTC 3700; 5550 5 CAPD 4 times a day
Willegaignon et al. (2010) 2010 CR 1 [131I]sodium iodine DTC 3700 5 CAPD NA
Yeyin et al. (2016) 2016 CS 3 [131I]sodium iodine DTC 2775 and 1850; 2775; 1850 5 HD 24 h, 48 h
  1. CAPD, continuous ambulatory peritoneal dialysis; CCS, case–control study; CHD, continuous haemodialysis; CKD, chronic kidney diseases; COS, cohort study; CR, case report; CS, case series; DTC, differentiated thyroid cancer; FTC, follicular thyroid cancer; GD, Graves' disease; HD, haemodialysis; IPD, intermittent peritoneal dialysis; NA, not available; PC, pheochromocytoma; PET/CT, positron emission tomography/computed tomography; PTC, papillary thyroid cancer; TC, thyroid cancer; TD, thyroid disease; TM, Theoretical model; TMNG, toxic multinodular goiter
  2. aAlthough the study describes hyperthyroidism as well, the reported case was treated with [131I]sodium iodine for thyroid cancer
  3. b12 patients were on dialysis, type and timing were not specified
  4. cIn this study a pharmacokinetic software model was developed and validated with data of 131I, 123I and 124I
  5. dPatients with a blood serum creatinine level > 1.1 mg/dl
  6. eThe findings in one patient were compared with two patients with mild to moderate renal function